FENC

Fennec Pharmaceuticals Inc. (FENC) | Rumor.io

Fennec Pharmaceuticals

FENC

Attention (50-day avg)0%

Attention rank (50-day avg)#3,505

Bullish sentiment (50-day avg)91%

Price to earnings ratio60.4

Market capitalization384M

Earnings per share-0.12

Dividend yield (TTM)—

Revenue (annual)44.6M

Net income (annual)-9.7M

Social

What share of all stock conversation is about FENC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 14

Fennec Pharmaceuticals Inc. (FENC) reported Q1 2026 sales of $15.1M, a 73% YoY increase, driven by strong demand for PEDMARK.
The company achieved its first quarter of positive net income ($0.2M) and reduced its loss to $201K, with full-year 2025 PEDMARK growth of 50% and Q1 2026 growth of 73%.
Fennec's cash, cash equivalents, and projected PEDMARK revenues are expected to be sufficient to fund its business throughout 2026, positioning the company for sustained growth.

Generated by AI

Sentiment

Of the messages about FENC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -100	83.33% -11.51
Bearish	—	—	100% new	16.67% +11.51

Bullish· Sep 21

$FENC is up 12% on the day, with volume already double what it was yesterday, indicating a strong bullish trend.
Fennec Pharmaceuticals is undervalued and has room for significant growth, with peak sales potentially reaching $100M and a market cap of $500M, 2-2.5 times its current value.
The company has a $45M fundling in place for launch, with FDA approval on the horizon, and Wedbush has reaffirmed an "outperform" rating with a $11.00 price target.

Bearish· Nov 29

Fennec Pharmaceuticals Inc. expects to receive a Complete Response Letter from the FDA, indicating a rejection of its Pedmark application.
The FDA cited "deficiencies" following an inspection of the company's manufacturing facility, which led to a 40%+ decline in shares.
The company's management has been criticized for failing to address issues with its Pedmark application, with some investors expressing frustration and disappointment in the company's leadership.

Generated by AI

Topics

Of the messages about FENC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	61.94%
Technical Analysis	—	—	0%	13.43%
Earnings	—	—	0%	16.42%
Analysts	—	—	0%	8.21%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%

Earnings· Nov 13

Fennec Pharmaceuticals Inc. (FENC) has released its Q3 earnings report.

Announcements· Mar 18

Fennec Pharmaceuticals has entered into an exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand.
Under the terms of the agreement, Fennec will receive €40 million in upfront consideration and up to €210 million in additional commercial and regulatory milestone payments, plus double-digit tiered royalties on net sales of PEDMARQSI.
Fennec will also receive a €43 million upfront payment, plus up to €226 million in future commercial and regulatory milestones, in addition to the royalties on PEDMARQSI sales by Norgine.

Generated by AI

Community

Of the messages about FENC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	47.37%	33.08%
Newcomers	—	—	52.63%	66.92%

Regulars· Jan 31

Fennec Pharmaceuticals' PEDMARK (sodium thiosulfate injection) receives Orphan Drug Exclusivity from the U.S. FDA, potentially expanding its market.
Analysts are highly confident in Fennec Pharmaceuticals, with a buy consensus of 83% among 12 analysts who have analyzed the stock.
Fennec Pharmaceuticals is expected to report a loss of $0.84 per share in its FY2022 earnings, according to a forecast from HC Wainwright.

Newcomers· Sep 21

Fennec Pharmaceuticals secured up to $45M in debt financing, contingent on FDA approval of Pedmark, and has now received approval after three attempts.
Fennec Pharmaceuticals' shares are up over 12% after Pedmark's FDA approval, but the company's capital to commercialize the drug is limited to $14.9M.
The unusual high put volume on Fennec Pharmaceuticals suggests investors are concerned about the company's ability to capitalize on Pedmark's approval.

Generated by AI

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Sensorineural Hearing Loss pipeline constitutes 18+ key companies continuously working towards developing 20+ Sensorineural Hearing Loss treatment therapies, analysis of C...

2mo agoBarchart.com

Also Discussed

Investors talking about FENC also mention

#	Name	Attention
1	Eton Pharmaceuticals, Inc.ETON	0%-0.01
2	Aldeyra Therapeutics, Inc.ALDX	0%+0
3	TRVN - Trevena, Inc.	——
4	Lipocine Inc.LPCN	0%new
5	SCPH - scPharmaceuticals Inc.	——
6	Clearside Biomedical Inc.CLSD	0%0
7	RVNC - Revance Therapeutics, Inc.	——
8	ETNB - 89bio, Inc.	——
9	ADVM - Adverum Biotechnologies, Inc.	——
10	DBV Technologies S.A. Sponsored ADRDBVT	0%0

Fennec Pharmaceuticals Inc.

Healthcare
Biotechnology

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments that address ototoxicity, a form of hearing damage associated with certain cancer therapies. Its lead product, PEDMARK, is designed to reduce the risk of platinum-induced hearing loss in pediatric patients receiving cisplatin-based chemotherapy. The company operates in the biotechnology and oncology supportive-care markets, serving hospitals, pediatric oncology specialists, and healthcare providers involved in cancer treatment. Based in Research Triangle Park, North Carolina, Fennec Pharmaceuticals is positioned as a commercial-stage company centered on a targeted therapy that supports quality of care for children undergoing chemotherapy.

Website

Location

68 TW Alexander Drive

Research Triangle Park, NC, 27709

United States

Social

What share of all stock conversation is about FENC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 14

Fennec Pharmaceuticals Inc. (FENC) reported Q1 2026 sales of $15.1M, a 73% YoY increase, driven by strong demand for PEDMARK.
The company achieved its first quarter of positive net income ($0.2M) and reduced its loss to $201K, with full-year 2025 PEDMARK growth of 50% and Q1 2026 growth of 73%.
Fennec's cash, cash equivalents, and projected PEDMARK revenues are expected to be sufficient to fund its business throughout 2026, positioning the company for sustained growth.

Generated by AI

Sentiment

Of the messages about FENC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -100	83.33% -11.51
Bearish	—	—	100% new	16.67% +11.51

Bullish· Sep 21

$FENC is up 12% on the day, with volume already double what it was yesterday, indicating a strong bullish trend.
Fennec Pharmaceuticals is undervalued and has room for significant growth, with peak sales potentially reaching $100M and a market cap of $500M, 2-2.5 times its current value.
The company has a $45M fundling in place for launch, with FDA approval on the horizon, and Wedbush has reaffirmed an "outperform" rating with a $11.00 price target.

Bearish· Nov 29

Fennec Pharmaceuticals Inc. expects to receive a Complete Response Letter from the FDA, indicating a rejection of its Pedmark application.
The FDA cited "deficiencies" following an inspection of the company's manufacturing facility, which led to a 40%+ decline in shares.
The company's management has been criticized for failing to address issues with its Pedmark application, with some investors expressing frustration and disappointment in the company's leadership.

Generated by AI

Topics

Of the messages about FENC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	61.94%
Technical Analysis	—	—	0%	13.43%
Earnings	—	—	0%	16.42%
Analysts	—	—	0%	8.21%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%

Earnings· Nov 13

Fennec Pharmaceuticals Inc. (FENC) has released its Q3 earnings report.

Announcements· Mar 18

Fennec Pharmaceuticals has entered into an exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand.
Under the terms of the agreement, Fennec will receive €40 million in upfront consideration and up to €210 million in additional commercial and regulatory milestone payments, plus double-digit tiered royalties on net sales of PEDMARQSI.
Fennec will also receive a €43 million upfront payment, plus up to €226 million in future commercial and regulatory milestones, in addition to the royalties on PEDMARQSI sales by Norgine.

Generated by AI

Community

Of the messages about FENC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	47.37%	33.08%
Newcomers	—	—	52.63%	66.92%

Regulars· Jan 31

Fennec Pharmaceuticals' PEDMARK (sodium thiosulfate injection) receives Orphan Drug Exclusivity from the U.S. FDA, potentially expanding its market.
Analysts are highly confident in Fennec Pharmaceuticals, with a buy consensus of 83% among 12 analysts who have analyzed the stock.
Fennec Pharmaceuticals is expected to report a loss of $0.84 per share in its FY2022 earnings, according to a forecast from HC Wainwright.

Newcomers· Sep 21

Fennec Pharmaceuticals secured up to $45M in debt financing, contingent on FDA approval of Pedmark, and has now received approval after three attempts.
Fennec Pharmaceuticals' shares are up over 12% after Pedmark's FDA approval, but the company's capital to commercialize the drug is limited to $14.9M.
The unusual high put volume on Fennec Pharmaceuticals suggests investors are concerned about the company's ability to capitalize on Pedmark's approval.

Generated by AI

Fennec Pharmaceuticals

Social

May 14

Sentiment

Bullish· Sep 21

Bearish· Nov 29

Topics

Earnings· Nov 13

Announcements· Mar 18

Community

Regulars· Jan 31

Newcomers· Sep 21

News

Sensorineural Hearing Loss Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics

Also Discussed

Fennec Pharmaceuticals Inc.

Company Information

Location

Social

May 14

Sentiment

Bullish· Sep 21

Bearish· Nov 29

Topics

Earnings· Nov 13

Announcements· Mar 18

Community

Regulars· Jan 31

Newcomers· Sep 21

News

Sensorineural Hearing Loss Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics

Also Discussed